What the labs are producing.
An article joins this feed when it matches these terms. Each one is also a search of its own.
PHILADELPHIA, PA — Latus Bio has developed an experimental gene-delivery technology that achieved approximately five times greater kidney uptake than a conventional viral vector in preclinical testing, potentially addressing a major obstacle to developing gene therapies for kidney diseases. The Philadelphia…
Bioengineer.org News Source: Drew Townsend. (October 17, 2026). Frozen Shoulder Study Points to Scar Tissue Remodeling, Not Cell-Death Programs. Scienmag.
A novel Proteus mirabilis isolate yields an alkaline-stable laccase extremozyme that, paired with biogenic selenium nanoparticles, achieves complete cypermethrin degradation within 72 hours without toxic intermediates.
Marsha Tripp graduated from the University of Florida in the 1980s. Her son is now a sophomore at the Gainesville school, but she worried that his path to UF was tougher than hers because of the growing number of out-of-state students…
Bioengineer.org Chitosan nanoparticles could give tamoxifen a high-tech makeover News Source: Ophelia Keating. (October 17, 2026). Chitosan nanoparticles could give tamoxifen a high-tech makeover. Scienmag.
InfotechLead The latest VC funding deals include announcements on Estuary Biotherapeutics, Microbiotica, Undecimal Bio, Deep Track Capital, Biogen New Ventures, and others. Estuary Biotherapeutics Raises $93 Million Series A for Kidney Gene Therapy Development US biotechnology startup Estuary Biotherapeutics has launched…
The proceeds will support Estuary’s two lead programs, EST-201 and EST-101, through clinical proof of concept and further development of the company’s kidney-targeting platform. Both programs are designed to address the two most common genetic subtypes of ADPKD, an inherited…
Program First of its Kind in New Jersey Sep 21, 2011, 10:05 ET MORRISTOWN, N.J., Sept. 21, 2011 /PRNewswire/ -- Bruce I. Jacobs and Kenneth N. Levy, co-founders of Florham Park-based Jacobs Levy Equity Management, have donated $1 million to fund the Jacobs Levy Equity Management Personalized Genomic Medicine Program…
A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by more than 56 percent with acceptable short-term safety. Subject of Research: Efficacy and safety of the oral PCSK9 inhibitor enlicitide in hypercholesterolemia Article Title: Efficacy…
Researchers in Iraq have developed a completely plant-based route for building a zinc oxide–selenium nanocomposite that can both destroy dye pollutants under ultraviolet light and suppress clinically relevant pathogens, and their results point to a surprisingly precise recipe: just…